Floatz logo

Sorafenib

AML, Childhood

Children's Hospital of Soochow UniversitySmall moleculePhase 2/3Active
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
81/ 100

Competitive context

51 Active assets in the AML, Childhood cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Joanna Yi
Phase 3BBB
Cytosin-Arabinosid
Children's Oncology Group
Phase 3BBB
METHOTREXATE
Children's Oncology Group
Phase 3BBB
FILGRASTIM
National Cancer Institute (NCI)
Phase 3BBB
Cyclophosphamide
Fred Hutchinson Cancer Center
Phase 3BBB

View all 50 →

Same molecule, other indications

Sorafenib is also rated in:

renal cell carcinomaDormant
BBB
Indicative ·
79 / 100
View asset →
SorafenibDormant
BBB
Indicative ·
75 / 100
View asset →
portal vein thrombosisDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →